Economist Award for Bioscience Innovation Announced
13 October
J. Craig Venter has won this year's Economist Innovation Award for Bioscience. Dr Venter, president of the J. Craig Venter Institute (JCVI)(www.jcvi.org), Is to be honoured for his genomic research and its potential "to revolutionise personal medicine, pharmaceuticals and biofuels." At the forefront of genomic research for almost two decades, Dr Venter's discoveries have been said to open up the scientific research of the microbial world and how it affects humans.
Commenting on his award, Dr Venter said: "We are now in a world 100% dependent on scientific innovation. Innovation is the key driver for success, especially in challenging economic times."
The award will be presented at a ceremony at London's Science museum on October 29th. The Economist's Innovation Summit, focusing on the interface between innovation and business, will take place the following day.
For more information on the winner and the award, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
